Bristol Myers Squibb Shares Surge on FDA News

Bristol Myers Squibbs shares surged by 2.6% following a Guggenheim analysts upgrade to Buy and a new price target of $62, along with the FDAs priority review for Opdivo in treating Hodgkin Lymphoma. However, Morgan Stanley maintained an Underweight rating, and shares settled at $52.53, still up from the previous close. Despite todays move, the stock has been relatively stable, down 7.5% this year and 17% below its 52-week high. An investment of $1000 five years ago would now be worth around $875.85, reflecting the stock markets volatility and differing expert opinions.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.